Clinical Validation of Medasense Pain Response Index (PRI)

NACompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 25, 2014

Conditions
SurgeryPain
Interventions
DRUG

Base level of remifentanil effect side concentration: 2ng/ml

constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.

DRUG

Base level of remifentanil effect side concentration: 4ng/ml

constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.

OTHER

chronic beta-blocker treatment

Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.

Trial Locations (1)

31096

Rambam Health Care Campus, Haifa

Sponsors
All Listed Sponsors
lead

Medasense Biometrics Ltd

OTHER

NCT01762332 - Clinical Validation of Medasense Pain Response Index (PRI) | Biotech Hunter | Biotech Hunter